로그인 회원가입
icon_bulk_order대량 주문 조회 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > B7-H3

B7-H3

요약

Name:CD276 antigen
Target Synonym:B7 homolog 3,PSEC0249,UNQ309/PRO352,B7-H3,CD276 antigen,B7H3,CD276,CD276 Molecule,Costimulatory Molecule,4Ig-B7-H3,B7RP-2
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:14
Lastest Research Phase:NDA/BLA

라이센싱

항목 적응증 연구 단계 합작 수요
BDA202203 B7H3+ and PD-L1+/low cancer CMC development License-out or co-development

제품 리스트 비교 또는 구매

일부의 생물활성 데이터

B73-H52E2-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human B7-H3, His Tag (Cat. No. B73-H52E2) inhibits Anti-CD3-induced proliferation of PBMC. The EC50 for this effect is 2.24-3.36 μg/mL (Routinely tested).

B73-C52Ha-ELISA
Cynomolgus B7-H3, His TagCynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) ELISA bioactivity

Immobilized Cynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).

B73-C52Ha-MALS-HPLC
Cynomolgus B7-H3, His Tag (Cat. No. ) MALS images

The purity of Cynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) is more than 90% and the molecular weight of this protein is around 53-75 kDa verified by SEC-MALS.

Bioactivity-ELISA
Cynomolgus B7-H3, His TagCynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) ELISA bioactivity

Immobilized Cynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).

Synonym Name

B7-H3,CD276,B7 homolog 3

Background

B7 homolog 3 (B7-H3), a member of the immunoglobulin superfamily, is also known CD276, which contains two Ig-like C2-type (immunoglobulin-like) domains and two Ig-like V-type (immunoglobulin-like) domains. B7-H3 may participate in the regulation of T-cell-mediated immune response. B7-H3 also plays a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. Furthermore, B7-H3 is involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. It could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy.

Clinical and Translational Updates

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
SCRI-CARB7H3 SCRI-CARB7H3 Phase 1 Clinical Seattle Children'S Hospital Central Nervous System Neoplasms; Glioma Details
Monoclonal antibody 8H9 I-124 124I-8H9; 124I-8H9-(B7-H3) Phase 2 Clinical Memorial Sloan Kettering Cancer Center Glioma Details
Anti-CD276 CAR T-cell therapy (Persongen ) Phase 1 Clinical Persongen Biotherapeutics (Suzhou) Co Ltd Stomach Neoplasms; Osteosarcoma; Neuroblastoma; Lung Neoplasms Details
CD-276-targeted Chimeric Antigen Receptor T Cell Therapy CD276 CAR-T Shenzhen University General Hospital Details
Fully Human B7H3 CAR-T Cells Therapy fhB7H3.CAR-Ts The Affiliated Hospital Of Xuzhou Medical University Details
EGFR/B7H3 CAR-T EGFR/B7H3 CAR-T Second Affiliated Hospital Of Guangzhou Medical University Details
Obrindatamab MGD-009; B7-H3 x CD3 Phase 2 Clinical Macrogenics Rhabdomyosarcoma; Wilms Tumor; Sarcoma, Synovial; Neuroblastoma; Neurofibrosarcoma Details
B7-H3 CAR-T cell therapy (Zhejiang University) Zhejiang University Alumni Association (Singapore) Details
DS-5573 DS-5573; DS-5573a Daiichi Sankyo Co Ltd Details
TAA-06 TAA06-UCAR-γδT; TAA-06 Phase 1 Clinical Persongen Biotherapeutics (Suzhou) Co Ltd Solid tumours; Neuroblastoma; Colorectal Neoplasms; Lung Neoplasms; Melanoma Details
B7-H3-targeting CAR-T cell therapy Beijing Tiantan Hospital, Capital Medical University Details
BAT-8009 BAT8009; BAT-8009 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours Details
Enoblituzumab MGA-271; TJ271 Phase 2 Clinical Macrogenics Carcinoma, Transitional Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Sarcoma, Ewing; Osteosarcoma; Neuroblastoma; Urethral Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Wilms Tumor; Carcinoma, Renal Cell; Abdominal Neoplasms; Desmoplastic Small Round Cell Tumor; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma; Ovarian Neoplasms; Head and Neck Neoplasms Details
Vobramitamab duocarmazine MGC-018 Phase 1 Clinical Macrogenics Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Pancreatic Ductal; Melanoma Details
4SCAR-276 4SCAR-276 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Solid tumours Details
Mirzotamab clezutoclax ABBV-155 Phase 1 Clinical Abbvie Inc Solid tumours; Neoplasms Details
B7-H3 CAR T-cell therapy(Stanford University) B7-H3CART Phase 1 Clinical Stanford University Nervous System Diseases Details
Ifinatamab deruxtecan DS-7300; DS-7300a; MABX-9001a Phase 2 Clinical Daiichi Sankyo Co Ltd Solid tumours; Small Cell Lung Carcinoma Details

This web search service is supported by Google Inc.

totop